Skip navigation

Signatera looks deeper

San Antonio Breast Cancer Symposium
(SABCS) 2020 Virtual Meeting

Personalized tumor-informed test for actionable intelligence in breast cancer

Explore our two presentations at the 2020 San Antonio Breast Cancer Symposium (SABCS) virtual conference and access additional content below. The two posters highlight the unique applications of Signatera to detect recurrence using circulating-tumor DNA (ctDNA).

See our presentations from SABCS

Oral Presentation

Growing Number of Breast Cancer Studies with Signatera

Signatera has been used in clinical trials for over 500 Breast Cancer patients and that number is growing. See our two recently announced Breast Cancer studies:

Dare Study

Prospective Randomized Clinical Trial to Evaluate Palbociclib in Early Stage Breast Cancer Patients Who Test Positive with Signatera

LEADER Study Part 2

Study to use Signatera to test effectiveness of Ribociclib in combination with endocrine therapy versus standard endocrine therapy

Dive Deeper Into How Signatera Can Improve Your Breast Cancer Clinical Trial

Learn More

Sign up to our clinical trial mailing list (max 8 emails sent per year with only biggest announcements).

Reach out to oncologymeeting@natera.com to find out how Signatera can support your clinical trials and Breast Cancer patients.